CombiGene has entered into a new license agreement with Spark Therapeutics regarding intellectual property related to the epilepsy project, CG01. CombiGene's CEO Peter Ekolind believes that they are now in better position to find a new development partner who can take the epilepsy treatment all the way to patients and the market.
- We are looking for a partner who can pick up where Spark left off, and with the agreement in place, we can use the data generated over the past two years in our search, says Peter Ekolind.

Read the full article at biostock.se:

https://www.biostock.se/en/2024/06/combigene-positive-to-new-license-agreement-for-cg01/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

https://news.cision.com/combigene/r/biostock-combigene-positive-to-new-license-agreement-for-cg01,c4006770

(c) 2024 Cision. All rights reserved., source Press Releases - English